Allergan Aesthetics has published clinical findings on skin quality improvements in patients taking GLP-1 receptor agonists for weight loss. The study documents measurable changes in facial appearance, with patients reporting skin improvements alongside weight reduction. This is not marketing hype. The data comes from a controlled clinical evaluation and carries weight because it addresses a genuine phenomenon practices are already seeing in their chairs.
Market
Allergan's GLP-1 Skin Study: What Practices Need to Know
AbbVie's Allergan Aesthetics released clinical data on skin quality in weight-loss drug users—and the implications for your patient base are real.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Allergan's clinical data validates what practices are already seeing in GLP-1 patients.
For medspa owners, this matters in two ways. First, GLP-1 users represent a growing patient cohort with specific aesthetic needs—not just body contouring, but facial skin quality concerns that may differ from your traditional injectables clientele. Second, Allergan's willingness to publish this data signals that major manufacturers are taking the GLP-1 aesthetic trend seriously enough to invest in clinical validation. That validation becomes a sales tool for your consultations and a defense against skepticism from patients or referring physicians.
Source: original report ↗
Frequently asked questions
What did Allergan's GLP-1 skin study actually find?
Allergan Aesthetics published clinical data showing measurable improvements in skin quality and facial appearance in patients taking GLP-1 receptor agonists for weight loss. The study was a controlled clinical evaluation, not marketing material, and documents both skin improvements and weight reduction occurring together in the patient population.
Are GLP-1 users a different type of aesthetic patient?
Yes. GLP-1 users represent a growing cohort with specific aesthetic needs beyond traditional body contouring—they often present with facial skin quality concerns that differ from standard injectables clientele. Understanding this distinction helps practices tailor consultations and treatment plans to their unique needs.
How should medspa practices use Allergan's GLP-1 data in consultations?
The clinical validation from Allergan becomes a credible sales tool during patient consultations and helps defend against skepticism from patients or referring physicians. You can reference the controlled study data when discussing skin quality improvements and positioning complementary aesthetic treatments for GLP-1 users.
Why are major aesthetic manufacturers investing in GLP-1 research?
Allergan's decision to publish clinical data signals that the GLP-1 aesthetic trend is significant enough to warrant manufacturer investment in clinical validation. This reflects the reality that practices are already seeing GLP-1-related skin changes in their patient chairs, making it a legitimate business priority for the industry.
What aesthetic concerns should practices screen for in GLP-1 patients?
GLP-1 patients often present with facial skin quality concerns alongside weight loss, requiring practices to assess beyond standard body contouring needs. Allergan's study validates that skin improvements occur in this population, but individual needs may vary—consultation should address both facial appearance and skin quality goals.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.